Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
09/2010
09/02/2010US20100222285 Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation
09/02/2010US20100222279 Composition for animal consumption and method for reducing map kinase activity
09/02/2010US20100222274 Glycosylation-deficient hepatocyte growth factor
09/02/2010US20100222264 Use of rgd-enriched gelatine-like proteins for inhibition of cancer metastasis
09/02/2010US20100222263 Atap peptides, nucleic acids encoding the same and associated methods of use
09/02/2010US20100222258 TNF antagonist and TNF inhibitor containing it as an effective ingredient
09/02/2010US20100222256 Novel polypeptide anti-HIV agent containing the same
09/02/2010US20100222234 Malaria antigen screening method
09/02/2010US20100221761 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
09/02/2010US20100221365 Use of ginseng fractions for preventing or reducing hematological malignancies
09/02/2010US20100221357 Drug delivery product and methods
09/02/2010US20100221351 Controlled Drug Delivery Using a Thermally Responsive Nanocapsule to Augment Cryoablation
09/02/2010US20100221331 Pharmaceutical compositions comprising colloidal silicon dioxide
09/02/2010US20100221330 Buoyant formulations of betaine
09/02/2010US20100221317 Dynamin mediated diseases and associated methods and products
09/02/2010US20100221305 Formulations for coated microprojections containing non-volatile counterions
09/02/2010US20100221289 Method for treating stage iv melanoma
09/02/2010US20100221267 Pdgfr beta-specific inhibitors
09/02/2010US20100221266 Methods to regulate mirna processing by targeting lin-28
09/02/2010US20100221262 Anti-unc5b antibodies and methods of use
09/02/2010US20100221261 Iap bir domain binding compounds
09/02/2010US20100221259 Nitrogen-containing heterocyclic compounds and medicinal use thereof
09/02/2010US20100221257 Binding members-513
09/02/2010US20100221254 Methods and Compositions for PDGF-C Activation and Inhibition
09/02/2010US20100221251 Compositions and Methods for Treatment of Cancer
09/02/2010US20100221250 Methods of treating brain tumors with antibodies
09/02/2010US20100221249 Wisp polypeptides and nucleic acids encoding same
09/02/2010US20100221248 Directed Engagement of Activating Fc Receptors
09/02/2010US20100221247 Agents and methods for treatment of cancer
09/02/2010US20100221246 Methods and compositions for treating cancer
09/02/2010US20100221230 Elective Collection and Banking of Autologous Peripheral Blood Stem Cells
09/02/2010US20100221228 y134.5 Deficient HSV and the MAPK Pathway
09/02/2010US20100221222 Interferons, uses and compositions related thereto
09/02/2010US20100221221 N-phenyl-2-pyrimidineamine derivatives
09/02/2010US20100221220 Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
09/02/2010US20100221218 Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
09/02/2010US20100221213 Y-shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
09/02/2010US20100221212 Proproteins and methods of use thereof
09/02/2010US20100221211 Pyridone-substituted-dihydropyrazolopyrimidinone derivative
09/02/2010US20100221210 Dimeric Alpha Interferon PEGylated Site-Specifically Shows Enhanced and Prolonged Efficacy in Vivo
09/02/2010US20100221195 Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
09/02/2010US20100221179 IL-1 Binding Proteins
09/02/2010US20100221177 RS7 Antibodies
09/02/2010US20100221176 Methods and compositions for protein labelling
09/02/2010CA2753827A1 Apparatus, system, and method for creating immunologically enhanced spaces in-vivo
09/02/2010CA2753804A1 Compositions and methods for visualizing and eliminating cancer stem cells
09/02/2010CA2753604A1 Drug combinations containing pde4-inhibitors and nsaids
09/02/2010CA2753597A1 Drug combinations containing pde4-inhibitors and nsaids
09/02/2010CA2753562A1 Micrornas in never-smokers and related materials and methods
09/02/2010CA2753304A1 Tricyclic pyrazolopyrimidine derivatives as hsp inhibitors
09/02/2010CA2753261A1 Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity
09/02/2010CA2753041A1 Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
09/02/2010CA2752885A1 Jak kinase modulating quinazoline derivatives and methods of use thereof
09/02/2010CA2750716A1 Pyrimidopyrimidoindazole derivative
09/02/2010CA2749403A1 Pyrimidinecarboxamide derivatives as inhibitors of syk kinase
09/01/2010EP2224003A2 MicroRNA molecules
09/01/2010EP2223939A1 Transgenic mice used as models for human pathologies originating from stem cells
09/01/2010EP2223933A1 Genes encoding major capsid protein l1 of human papilloma viruses
09/01/2010EP2223932A1 Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
09/01/2010EP2223929A1 Gambogic glycoside derivatives and analogs, the preparation and the application thereof
09/01/2010EP2223927A2 Cyclic phosphonic acid based prodrugs of PMEA and its analogues
09/01/2010EP2223925A1 Kinase inhibitors
09/01/2010EP2223920A2 Substituted azabicyclic compounds
09/01/2010EP2223914A1 Tricyclic condensed pyrazole derivatives as CB1 inhibitors
09/01/2010EP2223688A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
09/01/2010EP2223687A1 (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of Using and Compositions Thereof
09/01/2010EP2223683A1 Oral powder and granular antitumor agent
09/01/2010EP2222709A2 Antigen-binding constructs
09/01/2010EP2222690A2 Natural brassinosteroids for use for treating hyperproliferation, treating proliferative diseases and reducing adverse effects of steroid dysfunction in mammals, pharmaceutical composition and its use
09/01/2010EP2222682A1 Imidazo-thiazole derivatives as protein kinase inhibitors
09/01/2010EP2222675A1 5-anilinoimidazopyridines and methods of use
09/01/2010EP2222648A1 Pyrimidine derivatives for the treatment of asthma, copd, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, cancer, hepatitis b, hepatitis c, hiv, hpv, bacterial infections and dermatosis
09/01/2010EP2222641A1 A new inhibitor of dd-peptidase and its use as antibiotic or anticancer drug
09/01/2010EP2222328A1 Method of administering conjugates
09/01/2010EP2222323A2 A process of making purified extract of scutellaria barbata d. don
09/01/2010EP2222322A1 Scutellaria barbata extract and combinations for the treatment of cancer
09/01/2010EP2222304A2 Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
09/01/2010EP2222298A1 Use of cfms inhibitor for treating or preventing bone cancer and the bone loss and bone pain associated with bone cancer
09/01/2010EP2222276A1 Stable elsamitrucin salt formulations
09/01/2010EP2222166A1 Heterocyclic kinase inhibitors
09/01/2010EP2125793B1 Imidazolidinonyl aminopyrimidine compounds for the treatment of cancer
09/01/2010EP1864683B1 Radiotherapy enhancer
09/01/2010EP1854787B1 Novel cyclic compound having quinolylalkylthio group
09/01/2010EP1812439B1 Kinase inhibitors
09/01/2010EP1469809B1 Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same
09/01/2010EP1430027B1 Novel aminoazetidine, -pyrrolidine and -piperidine derivatives
09/01/2010EP1423406B1 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
09/01/2010EP1379508B1 N-(aryl)-2-arylethenesulfonamides and therapeutic uses thereof
09/01/2010EP1337558B1 A "bach" g protein coupled receptor polypeptide and polynucleotide encoding this receptor
09/01/2010EP1028942B1 Dipeptide nitriles
09/01/2010CN1995065B Fusion protein for suppressing PTTG expression and its coding gene and uses
09/01/2010CN1903876B Polypeptide, nucleic acid molecule coding it and use
09/01/2010CN1836729B Target antibody compound for killing tumour cell and its preparation method
09/01/2010CN1523997B Stabilized interleukin 2
09/01/2010CN101821292A Combination therapy with type i and type ii anti-cd20 antibodies
09/01/2010CN101821274A Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof
09/01/2010CN101821270A 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1
09/01/2010CN101821269A 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2
09/01/2010CN101821255A 2-morpholin-4-yl-pyrimidines as PI3K inhibitors
09/01/2010CN101821253A Piperidine derivative
1 ... 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 ... 2211